Marcus Koch joins Holger Müller in the management team of Health Advances GmbH. He will primarily advise clients in the biopharmaceutical industry as well as investors in the broader healthcare environment and will continue to drive the growth course in the European consulting business.
Marcus Koch brings over 15 years of experience in strategy development, commercialization and investment in the life sciences sector. Before joining Health Advances, he worked as an equity analyst for the European pharmaceutical sector at UBS Investment Bank in Zurich and London, where he established himself as an expert in the areas of healthcare systems, market access, reimbursement and pricing of medicines in the investor environment. He previously worked for the biotech company Amgen in Zug, initially responsible for strategic planning in the International region. He then gained local experience at Amgen's Swiss subsidiary as a product manager, where he prepared the launch of new products in nephrology and immunology, among other things. Most recently, as head of medical strategy in Europe, he helped establish the new patient affairs function. He started his career at the consulting firms Bain & Company and Booz & Company with a focus on strategy development for clients in the biopharmaceutical industry.
Marcus Koch studied pharmacy at the University of Freiburg im Breisgau and did his doctorate in medicinal chemistry at the Technical University of Dortmund. He holds a University Diploma in Drug Market Access from the University of Aix-Marseille and is a Chartered Financial Analyst (CFA).